Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based …
J Stomper, JC Rotondo, G Greve, M Lübbert - Leukemia, 2021 - nature.com
Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
Y Nannya, M Tobiasson, S Sato, E Bernard… - Blood …, 2023 - ashpublications.org
Azacitidine is a mainstay of therapy for myelodysplastic syndrome (MDS)–related diseases.
The purpose of our study is to elucidate the effect of gene mutations on hematological …
The purpose of our study is to elucidate the effect of gene mutations on hematological …
Unravelling the epigenome of myelodysplastic syndrome: Diagnosis, prognosis, and response to therapy
Simple Summary Myelodysplastic syndrome (MDS) is a type of blood cancer that mostly
affects older individuals. Invasive tests to obtain bone samples are used to diagnose MDS …
affects older individuals. Invasive tests to obtain bone samples are used to diagnose MDS …
[HTML][HTML] Effects of 5-aza on neurogenesis contribute to learning and memory in the mouse hippocampus
Z Chang, W Xu, S Jiang, X Liu, H Zhu, P Wang… - Biomedicine & …, 2022 - Elsevier
Abstract Background 5-Aza-2′-deoxycytidine (5-Aza-CdR) is a demethylating agent that
has various biological effects related to DNA methylation. DNA methylation plays important …
has various biological effects related to DNA methylation. DNA methylation plays important …
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy
There are currently no known predictors of myelodysplastic syndrome (MDS)/
myeloproliferative overlap neoplasm (MPN) patients' response to hypomethylating agents …
myeloproliferative overlap neoplasm (MPN) patients' response to hypomethylating agents …
Noncoding RNAs and their response predictive value in azacitidine-treated patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia …
MD Merkerova, J Klema, D Kundrat… - Cancer Genomics & …, 2022 - cgp.iiarjournals.org
Background/Aim: Prediction of response to azacitidine (AZA) treatment is an important
challenge in hematooncology. In addition to protein coding genes (PCGs), AZA efficiency is …
challenge in hematooncology. In addition to protein coding genes (PCGs), AZA efficiency is …
Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML
Background As new treatment options for patients with higher-risk myelodysplastic
syndromes are emerging, identification of prognostic markers for hypomethylating agent …
syndromes are emerging, identification of prognostic markers for hypomethylating agent …
Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine
A Bouchla, TP Thomopoulos, SG Papageorgiou… - …, 2021 - Taylor & Francis
5-Azacitidine (5-AZA) is widely used for the treatment of higher-risk myelodysplastic
syndromes. However, response and survival rates vary considerably, while indicated …
syndromes. However, response and survival rates vary considerably, while indicated …
Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a …
P Jeanselme, S Tavitian, L Lapierre, F Vergez… - Leukemia & …, 2024 - Taylor & Francis
Adult T-cell acute lymphoblastic leukemia has a poor outcome after relapse. Because the
subtype of early T-cell precursor displays characteristics close of those of acute myeloid …
subtype of early T-cell precursor displays characteristics close of those of acute myeloid …
Low-Dose 5-Aza and DZnep Alleviate Acute Graft-Versus-Host Disease With Less Side Effects Through Altering T-Cell Differentiation
QY Wang, HH Liu, YJ Dong, ZY Liang, Y Yin… - Frontiers in …, 2022 - frontiersin.org
Objective Previous studies showed that hypomethylating agents (HMAs) could alleviate
acute graft-versus-host disease (aGvHD), but affect engraftment after allogeneic …
acute graft-versus-host disease (aGvHD), but affect engraftment after allogeneic …